6.
Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel A
. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2016; 32(5):870-879.
DOI: 10.1093/ndt/gfw042.
View
7.
Kalim S, Clish C, Wenger J, Elmariah S, Yeh R, Deferio J
. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013; 2(6):e000542.
PMC: 3886735.
DOI: 10.1161/JAHA.113.000542.
View
8.
Foreman K, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M
. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018; 392(10159):2052-2090.
PMC: 6227505.
DOI: 10.1016/S0140-6736(18)31694-5.
View
9.
Vanholder R, Nigam S, Burtey S, Glorieux G
. What If Not All Metabolites from the Uremic Toxin Generating Pathways Are Toxic? A Hypothesis. Toxins (Basel). 2022; 14(3).
PMC: 8953523.
DOI: 10.3390/toxins14030221.
View
10.
Niewczas M, Mathew A, Croall S, Byun J, Major M, Sabisetti V
. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care. 2017; 40(3):383-390.
PMC: 5319475.
DOI: 10.2337/dc16-0173.
View
11.
Matsushita K, Ballew S, Yee-Moon Wang A, Kalyesubula R, Schaeffner E, Agarwal R
. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease. Nat Rev Nephrol. 2022; 18(11):696-707.
DOI: 10.1038/s41581-022-00616-6.
View
12.
Jankowski J, Luftmann H, Tepel M, Leibfritz D, Zidek W, Schluter H
. Characterization of dimethylguanosine, phenylethylamine, and phenylacetic acid as inhibitors of Ca2+ ATPase in end-stage renal failure. J Am Soc Nephrol. 1998; 9(7):1249-57.
DOI: 10.1681/ASN.V971249.
View
13.
Mjelva O, Svingen G, Pedersen E, Seifert R, Kvaloy J, Midttun O
. Fibrinogen and Neopterin Is Associated with Future Myocardial Infarction and Total Mortality in Patients with Stable Coronary Artery Disease. Thromb Haemost. 2018; 118(4):778-790.
DOI: 10.1055/s-0038-1629912.
View
14.
Tendulkar K, Cope B, Dong J, Plumb T, Campbell W, Ganti A
. Risk of malignancy in patients with chronic kidney disease. PLoS One. 2022; 17(8):e0272910.
PMC: 9385037.
DOI: 10.1371/journal.pone.0272910.
View
15.
Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A
. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010; 2(46):46ps42.
DOI: 10.1126/scitranslmed.3001249.
View
16.
Vanholder R, Eloot S, Glorieux G
. Future Avenues to Decrease Uremic Toxin Concentration. Am J Kidney Dis. 2015; 67(4):664-76.
DOI: 10.1053/j.ajkd.2015.08.029.
View
17.
Wang H, Gamboa C, Warnock D, Muntner P
. Chronic kidney disease and risk of death from infection. Am J Nephrol. 2011; 34(4):330-6.
PMC: 3169360.
DOI: 10.1159/000330673.
View
18.
Rosner M, Reis T, Husain-Syed F, Vanholder R, Hutchison C, Stenvinkel P
. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021; 16(12):1918-1928.
PMC: 8729494.
DOI: 10.2215/CJN.02660221.
View
19.
Luo S, Coresh J, Tin A, Rebholz C, Appel L, Chen J
. Serum Metabolomic Alterations Associated with Proteinuria in CKD. Clin J Am Soc Nephrol. 2019; 14(3):342-353.
PMC: 6419293.
DOI: 10.2215/CJN.10010818.
View
20.
Sekula P, Goek O, Quaye L, Barrios C, Levey A, Romisch-Margl W
. A Metabolome-Wide Association Study of Kidney Function and Disease in the General Population. J Am Soc Nephrol. 2015; 27(4):1175-88.
PMC: 4814172.
DOI: 10.1681/ASN.2014111099.
View